FIELD: medicine, therapy. SUBSTANCE: method involves the use of preparation lamivudin, (-)-cis-1-[2-(2-hydroxymethyl)-1,3-oxathiolane-5-yl]-cytosine. Treatment with lamivudin for 3 months at dose 100 mg/day, not less, results to 100% inhibition of hepatitis B virus DNA in patients. EFFECT: enhanced effectiveness of method. 5 cl, 3 tbl
Authors
Dates
1998-02-20—Published
1992-05-01—Filed